Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Безопасность ибандроновой кислоты при длительном применении
Безопасность ибандроновой кислоты при длительном применении
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Body J-J, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399–405.
2. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies. Br J Cancer 2004; 22; 90 (6): 1133–7.
3. Diel IJ. Ibandronate: a well tolerated intravenous and oral treatment for metastatic bone disease. Eur J Cancer Suppl 2004; 2: 13–6.
4. Conte PF, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. The Oncologist 2004; 9 (suppl. 4): 28–37.
5. Lyubimova NV, Kushlinsky NE, Lichinitser MR, Schlosser K. Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease. Clin Drug Investig 2003; 23 (11): 707–16.
6. Heidenreich A. Ibandronate in metastatic bone pain. Semin Oncol 2004; 31 (5 Suppl. 10): 67–72.
7. Семенов Н.Н., Новиков В.В., Личиницер М.Р., Shlosser K. Фармакокинетика Бондроната – бифосфоната III поколения при многократном внутривенном ведении. Клиническая фармакология и терапия. 2000; 3: 54–62.
8. Leyland-Jones B. Pharmacokinetic and clinical equivalence of oral and intravenous Ibandronate for metastatic bone disease. Eur J Cancer 2004; Suppl. 2: 9–12.
9. Ibrahim T, Barbanti F, Giorgio-Marrano G et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective trial. The Oncologist 2008; 13: 330–6.
10. Stopeck A et al. Denosumab vrsus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase III study. SABCS 2009; Abstract 22.
11.Vahtsevanos K et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.J Clin Oncol 2009; 27 (32): 5356–62.
2. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies. Br J Cancer 2004; 22; 90 (6): 1133–7.
3. Diel IJ. Ibandronate: a well tolerated intravenous and oral treatment for metastatic bone disease. Eur J Cancer Suppl 2004; 2: 13–6.
4. Conte PF, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. The Oncologist 2004; 9 (suppl. 4): 28–37.
5. Lyubimova NV, Kushlinsky NE, Lichinitser MR, Schlosser K. Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease. Clin Drug Investig 2003; 23 (11): 707–16.
6. Heidenreich A. Ibandronate in metastatic bone pain. Semin Oncol 2004; 31 (5 Suppl. 10): 67–72.
7. Семенов Н.Н., Новиков В.В., Личиницер М.Р., Shlosser K. Фармакокинетика Бондроната – бифосфоната III поколения при многократном внутривенном ведении. Клиническая фармакология и терапия. 2000; 3: 54–62.
8. Leyland-Jones B. Pharmacokinetic and clinical equivalence of oral and intravenous Ibandronate for metastatic bone disease. Eur J Cancer 2004; Suppl. 2: 9–12.
9. Ibrahim T, Barbanti F, Giorgio-Marrano G et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective trial. The Oncologist 2008; 13: 330–6.
10. Stopeck A et al. Denosumab vrsus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase III study. SABCS 2009; Abstract 22.
11.Vahtsevanos K et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.J Clin Oncol 2009; 27 (32): 5356–62.
Авторы
Н.Н.Семенов
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.